Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice

Authors: Masataka Ifuku, Toshihiko Katafuchi, Shiro Mawatari, Mami Noda, Kiyotaka Miake, Masaaki Sugiyama, Takehiko Fujino

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Background

Neuroinflammation involves the activation of glial cells in neurodegenerative diseases such as Alzheimer’s disease (AD). Plasmalogens (Pls) are glycerophospholipids constituting cellular membranes and play significant roles in membrane fluidity and cellular processes such as vesicular fusion and signal transduction.

Methods

In this study the preventive effects of Pls on systemic lipopolysaccharide (LPS)-induced neuroinflammation were investigated using immunohistochemistry, real-time PCR methods and analysis of brain glycerophospholipid levels in adult mice.

Results

Intraperitoneal (i.p.) injections of LPS (250 μg/kg) for seven days resulted in increases in the number of Iba-1-positive microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes in the prefrontal cortex (PFC) and hippocampus accompanied by the enhanced expression of IL-1β and TNF-α mRNAs. In addition, β-amyloid (Aβ3–16)-positive neurons appeared in the PFC and hippocampus of LPS-injected animals. The co-administration of Pls (i.p., 20 mg/kg) after daily LPS injections significantly attenuated both the activation of glial cells and the accumulation of Aβ proteins. Finally, the amount of Pls in the PFC and hippocampus decreased following the LPS injections and this reduction was suppressed by co-treatment with Pls.

Conclusions

These findings suggest that Pls have anti-neuroinflammatory and anti-amyloidogenic effects, thereby indicating the preventive or therapeutic application of Pls against AD.
Literature
1.
Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT: Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of β-amyloid generation. J Neuroinflammation 2008, 5:37.CrossRefPubMedPubMedCentral
2.
Deleidi M, Hallett PJ, Koprich JB, Chung CY, Isacson O: The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci 2010, 30:16091–16101.CrossRefPubMedPubMedCentral
3.
Okun E, Griffioen K, Barak B, Roberts NJ, Castro K, Pita MA, Cheng A, Mughal MR, Wan R, Ashery U, Mattson MP: Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. Proc Natl Acad Sci U S A 2010, 107:15625–15630.CrossRefPubMedPubMedCentral
4.
Blasko I, Apochal A, Boeck G, Hartmann T, Grubeck-Loebenstein B, Ransmayr G: Ibuprofen decreases cytokine-induced amyloid β production in neuronal cells. Neurobiol Dis 2001, 8:1094–1101.CrossRefPubMed
5.
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT: Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J Neurosci 2003, 23:9796–9804.PubMed
6.
Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G: Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci 2003, 23:7504–7509.PubMed
7.
Farooqui AA, Horrocks LA: Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 2001, 7:232–245.CrossRefPubMed
8.
Farooqui AA, Horrocks LA: Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J Mol Neurosci 2001, 16:263–272. discussion 279–284CrossRefPubMed
9.
Farooqui AA: Studies on plasmalogen-selective phospholipase A2 in brain. Mol Neurobiol 2010, 41:267–273.CrossRefPubMed
10.
Khaselev N, Murphy RC: Susceptibility of plasmenyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic Biol Med 1999, 26:275–284.CrossRefPubMed
11.
Engelmann B: Plasmalogens: targets for oxidants and major lipophilic antioxidants. Biochem Soc Trans 2004, 32:147–150.CrossRefPubMed
12.
Maeba R, Ueta N: Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem Biophys Res Commun 2003, 302:265–270.CrossRefPubMed
13.
Yavin E, Gatt S: Oxygen-dependent cleavage of the vinyl -ether linkage of plasmalogens. 2. Identification of the low-molecular-weight active component and the reaction mechanism. Eur J Biochem 1972, 25:437–446.CrossRefPubMed
14.
Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL: Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res 1995, 698:223–226.CrossRefPubMed
15.
Guan Z, Wang Y, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ: Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:740–747.CrossRefPubMed
16.
Han X, Holtzman DM, McKeel DW: Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001, 77:1168–1180.CrossRefPubMed
17.
Ginsberg L, Xuereb JH, Gershfeld NL: Membrane instability, plasmalogen content, and Alzheimer’s disease. J Neurochem 1998, 70:2533–2538.CrossRefPubMed
18.
Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL: Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 2007, 48:2485–2498.CrossRefPubMed
19.
Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, Goodenowe DB: Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiat Neurosci 2010, 35:59–62.CrossRef
20.
Perichon R, Moser AB, Wallace WC, Cunningham SC, Roth GS, Moser HW: Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Biochem Biophys Res Commun 1998, 248:57–61.CrossRefPubMed
21.
Mawatari S, Yunoki K, Sugiyama M, Fujino T: Simultaneous preparation of purified plasmalogens and sphingomyelin in human erythrocytes with phospholipase A1 from Aspergillus orizae. Biosci Biotechnol Biochem 2009, 73:2621–2625.CrossRefPubMed
22.
Mawatari S, Okuma Y, Fujino T: Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. Anal Biochem 2007, 370:54–59.CrossRefPubMed
23.
Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497–509.
24.
Boehm GW, Sparkman NL, Martin LA, Calvert WS: Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav Brain Res 2005, 159:145–151.CrossRefPubMed
25.
Shaw KN, Commins S, O’Mara SM: Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 2001, 124:47–54.CrossRefPubMed
26.
27.
Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B: TNFα plus IFNγ induce the production of Alzheimer β-amyloid peptides and decrease the secretion of APPs. FASEB J 1999, 13:63–68.PubMed
28.
Reiss D, Beyer K, Engelmann B: Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J 1997, 323:807–814.CrossRefPubMedPubMedCentral
29.
Zoeller RA, Grazia TJ, LaCamera P, Park J, Gaposchkin DP, Farber HW: Increasing plasmalogen levels protects human endothelial cells during hypoxia. Am J Physiol Heart Circ Physiol 2002, 283:H671-H679.CrossRefPubMed
30.
Urano S, Asai Y, Makabe S, Matsuo M, Izumiyama N, Ohtsubo K, Endo T: Oxidative injury of synapse and alteration of antioxidative defense systems in rats, and its prevention by vitamin E. Eur J Biochem 1997, 245:64–70.CrossRefPubMed
31.
Lohner K, Balgavy P, Hermetter A, Paltauf F, Laggner P: Stabilization of non-bilayer structures by the etherlipid ethanolamine plasmalogen. Biochim Biophys Acta 1991, 1061:132–140.CrossRefPubMed
32.
Breckenridge WC, Morgan IG, Zanetta JP, Vincendon G: Adult rat brain synaptic vesicles. II. Lipid composition. Biochim Biophys Acta 1973, 320:681–686.CrossRefPubMed
33.
Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ: Exclusively targeting β-secretase to lipid rafts by GPI-anchor addition up-regulates β-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 2003, 100:11735–11740.CrossRefPubMedPubMedCentral
34.
Riddell DR, Christie G, Hussain I, Dingwall C: Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 2001, 11:1288–1293.CrossRefPubMed
35.
Butterfield DA, Lauderback CM: Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002, 32:1050–1060.CrossRefPubMed
36.
Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000, 71:621S-629S.PubMed
37.
Grimm MOW, Kuchenbecker J, Rothhaar TL, Grosgen S, Hundsdorfer B, Burg VK, Friess P, Muller U, Grimm HS, Riemenschneider M, Hartmann T: Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease. J Neurochem 2011, 116:916–925.CrossRefPubMed
38.
Cimini A, Bernardo A, Cifone MG, Di Marzio L, Di Loreto S: TNFα downregulates PPARδ expression in oligodendrocyte progenitor cells: implications for demyelinating diseases. Glia 2003, 41:3–14.CrossRefPubMed
39.
Üllen A, Fauler G, Köfeler H, Waltl S, Nusshold C, Bernhart E, Reicher H, Leis HJ, Wintersperger A, Malle E, Sattler W: Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo. Free Rad Biol Med 2010, 49:1655–1665.CrossRefPubMedPubMedCentral
40.
Latorre E, Collado MP, Fernandez I, Aragones MD, Catalan RE: Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 2003, 270:36–46.CrossRefPubMed
41.
Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM: The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 1999, 10:1699–1705.CrossRefPubMed
42.
Puglielli L, Tanzi RE, Kovacs DM: Alzheimer’s disease: the cholesterol connection. Nat Neurosci 2003, 6:345–351.CrossRefPubMed
43.
Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L: Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 2003, 44:182–192.CrossRefPubMed
44.
Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, Su-Myat KK, Wood PL, Goodenowe DB: Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis 2010, 9:62.CrossRefPubMedPubMedCentral
45.
Chauhan NB: Membrane dynamics, cholesterol homeostasis, and Alzheimer’s disease. J Lipid Res 2003, 44:2019–2029.CrossRefPubMed
46.
Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K: Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998, 95:6460–6464.CrossRefPubMedPubMedCentral
47.
Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci U S A 2001, 98:5815–5820.CrossRefPubMedPubMedCentral
48.
49.
Farooqui AA, Horrocks LA, Farooqui T: Modulation of inflammation in brain: a matter of fat. J Neurochem 2007, 101:577–599.CrossRefPubMed
50.
Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Ashe KH, Frautschy SA, Cole GM: Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633–645.CrossRefPubMedPubMedCentral
51.
Palacios-Pelaez R, Lukiw WJ, Bazan NG: Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease. Mol Neurobiol 2010, 41:367–374.CrossRefPubMed
52.
Schmitz G, Ecker J: The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res 2008, 47:147–155.CrossRefPubMed
53.
Grimm MOW, Kuchenbecker J, Grosgen S, Burg VK, Hundsdorfer B, Rothhaar TL, Friess P, de Wilde MC, Broersen LM, Penke B, Péter M, Vígh L, Grimm HS, Hartmann T: Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 2011, 286:14028–14039.CrossRefPubMedPubMedCentral
54.
Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181–193.CrossRefPubMed
55.
Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006, 23:563–572.CrossRefPubMed
56.
Scott BL, Bazan NG: Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci U S A 1989, 86:2903–2907.CrossRefPubMedPubMedCentral
57.
Bernoud N, Fenart L, Moliere P, Dehouck MP, Lagarde M, Cecchelli R, Lecerf J: Preferential transfer of 2-docosahexaenoyl-1-lysophosphatidylcholine through an in vitro blood–brain barrier over unesterified docosahexaenoic acid. J Neurochem 1999, 72:338–345.CrossRefPubMed
58.
Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W, Braverman NE, Goodenowe DB: In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis 2011, 10:182.CrossRefPubMedPubMedCentral
59.
Candela P, Gosselet F, Miller F, Buee-Scherrer V, Torpier G, Cecchelli R, Fenart L: Physiological pathway for low-density lipoproteins across the blood–brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 2008, 15:254–264.CrossRefPubMed
Metadata
Title
Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice
Authors
Masataka Ifuku
Toshihiko Katafuchi
Shiro Mawatari
Mami Noda
Kiyotaka Miake
Masaaki Sugiyama
Takehiko Fujino
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-197

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue

Research

Pharmacokinetics and modeling of immune cell trafficking: quantifying differential influences of target tissues versus lymphocytes in SJL and lipopolysaccharide-treated mice

Research

Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease

Research

Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury

Research

c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells

Research

Indomethacin protects rats from neuronal damage induced by traumatic brain injury and suppresses hippocampal IL-1β release through the inhibition of Nogo-A expression

Research

Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation